According to Illumina's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.09183. At the end of 2021 the company had a P/E ratio of 74.7.
Year | P/E ratio | Change |
---|---|---|
2021 | 74.7 | -9.5% |
2020 | 82.6 | 69.54% |
2019 | 48.7 | -8.72% |
2018 | 53.4 | 22.13% |
2017 | 43.7 | 7.85% |
2016 | 40.5 | -32.66% |
2015 | 60.2 | -16.22% |
2014 | 71.8 | -35.06% |
2013 | 111 | 142.71% |
2012 | 45.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Thermo Fisher Scientific TMO | 33.7 | -575.61% | ๐บ๐ธ USA |
![]() Agilent Technologies A | 26.2 | -469.44% | ๐บ๐ธ USA |
![]() Quest Diagnostics
DGX | 16.7 | -336.00% | ๐บ๐ธ USA |
![]() Danaher DHR | 25.3 | -456.30% | ๐บ๐ธ USA |
![]() PerkinElmer
PKI | 25.1 | -454.08% | ๐บ๐ธ USA |
![]() Translate Bio
TBIO.defunct | N/A | N/A | ๐บ๐ธ USA |
![]() Pacific Biosciences
PACB | -10.1 | 41.72% | ๐บ๐ธ USA |
![]() Luminex LMNX | N/A | N/A | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.